Transforming Patient Care
Nexalis Therapeutics (ASX:NX1) is a clinical-stage biopharmaceutical company advancing innovative therapies for pain and mental health, addressing areas of profound unmet medical need.
Our diversified pipeline comprises three clinical drug candidates targeting treatment-resistant depression, breakthrough cancer pain, and panic disorder—indications with significant patient burden and compelling commercial potential.
By leveraging oral and inhaled drug-delivery technologies, we aim to deliver differentiated therapies designed to enhance efficacy, improve patient experience, and meaningfully elevate quality of life. Backed by an experienced leadership team, Nexalis is focused on efficiently advancing its programs through clinical development and toward commercialisation.
Leading Innovation in
Pain & Mental Health
Nexalis Therapeutics represents the next phase of our evolution—building on a strong foundation in inhaled drug-device expertise while expanding into oral drug delivery to unlock broader therapeutic potential. Supported by a total funding facility of $52.3 million, we are well positioned to advance our clinical programs and deliver meaningful, patient-centric therapies in pain and mental health.
Darryl Davies
Chief Executive Officer
Therapeutic Areas
We are developing innovative therapies across two critical therapeutic areas - pain management and mental health - using both oral and inhaled drug delivery modalities.
Our pipeline targets conditions with significant unmet medical needs, including treatment-resistant depression, breakthrough cancer pain, and panic disorder.
By leveraging the FDA 505(b)(2) regulatory pathway, we can accelerate development timelines while building on established safety profiles.